Clinical trials: Melanoma Stage III
Melanoma
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
This study is an open-label, Phase Ib clinical study to evaluate recombinant human GM-CSF herpes simplex virus intratumoral injection (OrienX010) in combination with recombinant humanized anti-PD-1 monoclonal antibody infusion…
- Trial name
- NCT04197882
- Testing
- OrienX010 Combination with Toripalimab injection
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma (Skin)
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00565968
- Testing
- melphalan, sorafenib tosylate, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Melanoma
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
- Trial name
- NCT01515189
- Testing
- Ipilimumab
- Where
- 88 sites in United States, Argentina and 20 more
- Volunteers
- 831 people
- Sponsor
- Bristol-Myers Squibb
Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
This phase I/II trial studies the side effects and how well pembrolizumab and imatinib mesylate work in treating patients with melanoma with c-KIT mutation or amplification that has spread to nearby tissue or other places in the…
- Conditions
- Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT02812693
- Testing
- Imatinib Mesylate, Laboratory Biomarker Analysis, Pembrolizumab
- Sponsor
- Joanne Jeter
Melanoma, Recurrent Melanoma
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma.
- Conditions
- Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00349206
- Testing
- sorafenib tosylate, temsirolimus
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004184
- Testing
- monoclonal antibody 4B5 anti-idiotype vaccine, sargramostim, alum adjuvant
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham
Advanced Melanoma
Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut
It is a single-center, single-arm Phase II clinical study. This clinical trial aimed to evaluate the PFS of imatinib combined with toripalimab in stage III unresectable and stage IV melanoma with CKIT gene mutation.
- Trial name
- NCT05274438
- Testing
- JS001+Imatinib mesylate
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00390338
- Testing
- polarized dendritic cells, non-polarized dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pawel Kalinski
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response. Combining vaccine therapy with interleukin-12 and either alum or sargramostim may kill more tumor cells.
- Trial name
- NCT00031733
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Southern California
Recurrent Melanoma, Stage IIIA Skin Melanoma
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph…
- Conditions
- Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
- Trial name
- NCT00019682
- Testing
- Aldesleukin, gp100 Antigen, Montanide ISA 51 VG
- Where
- 19 sites in United States
- Volunteers
- 185 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00003715
- Testing
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- 17 sites in United States
- Volunteers
- 425 people
- Sponsor
- AVAX Technologies
Advanced Malignant Solid Neoplasm, Recurrent Melanoma
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01303341
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Melanoma
CPG 7909 Injection in Melanoma
To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.
- Trial name
- NCT00070642
- Testing
- CPG 7909 Injection, dacarbazine, Chemotherapy
- Volunteers
- 184 people
- Sponsor
- Pfizer
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Metastatic Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response…
- Conditions
- Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- SERPENTINE (NCT04941365)
- Testing
- single arm
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Melanoma, Malignant Melanoma
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT01321437
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Irvine
Melanoma
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
This is a Phase 1b, open-label, dose-escalation cohort study. The study will consist of a dose escalation assessment of the safety and tolerability of Mocetinostat administered concurrently in combination with ipilimumab and…
- Trial name
- NCT03565406
- Testing
- Mocetinostat Induction Phase + Ipilimumab + Nivolumab, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Melanoma, Cancer
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
- Trial name
- PREMIUM (NCT05097378)
- Testing
- Encorafenib + Binimetinib, Standard Adjuvant Treatment
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- CCTU- Cancer Theme
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr